Dronedarone Tablets

<table>
<thead>
<tr>
<th>Type of Posting</th>
<th>Notice of Intent to Revise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posting Date</td>
<td>26-Aug-2022</td>
</tr>
<tr>
<td>Targeted Official Date</td>
<td>To Be Determined, Revision Bulletin</td>
</tr>
<tr>
<td>Expert Committee</td>
<td>Small Molecules 2</td>
</tr>
</tbody>
</table>

In accordance with the Rules and Procedures of the Council of Experts and the Pending Monograph Guideline, this is to provide notice that the Small Molecules 2 Expert Committee intends to revise the Dronedarone Tablets monograph.

Based on the supporting data received from a manufacturer awaiting FDA approval, the Expert Committee proposes to add Dissolution Test 4 to accommodate drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). Labeling information has also been incorporated to support the inclusion of Dissolution Test 4.

The proposed revision is contingent on FDA approval of a product that meets the proposed monograph specifications. The proposed revision will be published as a Revision Bulletin and an official date will be assigned to coincide as closely as possible with the FDA approval of the associated product.

See below for additional information about the proposed text.¹

Should you have any questions, please contact Robyn Fales, Senior Scientist I (240-221-2047 or mp@usp.org).

¹ This text is not the official version of a USP–NF monograph and may not reflect the full and accurate contents of the currently official monograph. Please refer to the current edition of the USP–NF for official text.

USP provides this text to indicate changes that we anticipate will be made official once the product subject to this proposed revision under the Pending Monograph Program receives FDA approval. Once FDA approval is granted for the associated revision request, a Revision Bulletin will be posted that will include the changes indicated herein, as well as any changes indicated in the product’s final approval, combined with the text of the monograph as effective on the date of approval. Any revisions made to a monograph under the Pending Monograph Program that are posted without prior publication for comment in the Pharmacopeial Forum must also meet the requirements outlined in the USP Guideline on Use of Accelerated Processes for Revisions to the USP–NF.
Dronedarone Tablets

DEFINITION
Dronedarone Tablets contain an amount of dronedarone hydrochloride equivalent to NLT 95.0% and NMT 105.0% of the labeled amount of dronedarone free base (C_{31}H_{44}N_{2}O_{9}S).

IDENTIFICATION
• A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
• B. The UV absorption spectra of the dronedarone peak in the Sample solution exhibit maxima and minima at the same wavelengths as those of the corresponding peak of the Standard solution, as obtained in the Assay.

ASSAY
• Procedure
  Buffer: Combine 2.0 mL of triethylamine with 1 L of water and adjust with phosphoric acid to a pH of 3.0.
  Mobile phase: Acetonitrile and Buffer (50:50)
  System suitability stock solution: 0.2 mg/mL each of USP Dronedarone Hydrochloride RS and USP Dronedarone Related Compound A RS in methanol
  System suitability solution: 0.01 mg/mL each of USP Dronedarone Hydrochloride RS and USP Dronedarone Related Compound A RS in Mobile phase from the System suitability stock solution
  Standard stock solution: 2.13 mg/mL of USP Dronedarone Hydrochloride RS in methanol
  Standard solution: 0.11 mg/mL of USP Dronedarone Hydrochloride RS in Mobile phase from the Standard stock solution
  Sample stock solution: Nominally equivalent to 4 mg/mL of dronedarone in methanol prepared as follows. Dissolve and dilute in methanol to volume, an amount equivalent to 400 mg of dronedarone from NLT 20 finely powdered Tablets, taken in a 100-mL volumetric flask. Sonicate for about 5 min and allow to settle at room temperature.
  Sample solution: Nominally equivalent to 0.1 mg/mL of dronedarone in Mobile phase from the Sample stock solution. Pass through a suitable filter of 0.45-µm pore size and discard the first 3 mL of the filtrate.

Chromatographic system
(See Chromatography (621), System Suitability.)
  Mode: LC
  Detectors
    Assay: UV 288 nm
    Identification test B: UV diode array
  Column: 4.6-mm × 25-cm; 5-µm packing L10
  Flow rate: 0.8 mL/min
  Injection volume: 20 µL
  Run time: NLT 2.15 times the retention time of dronedarone

System suitability
  Sample: System suitability solution
  [Note—The relative retention times for dronedarone related compound A and dronedarone are 0.7 and 1.0, respectively.]

Suitability requirements
  Resolution: NLT 8 between dronedarone and dronedarone related compound A
**Tailing factor:** 0.8–2.1 for dronedarone

**Relative standard deviation:** NMT 1.5%, for dronedarone

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of dronedarone free base \((C_{31}H_{44}N_2O_5S)\) in the portion of Tablets taken:

\[
\frac{(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2})}{100}
\]

- \(r_U\) = peak response of dronedarone from the *Sample solution*
- \(r_S\) = peak response of dronedarone from the *Standard solution*
- \(C_S\) = concentration of *USP Dronedarone Hydrochloride RS* in the *Standard solution* (mg/mL)
- \(C_U\) = nominal concentration of dronedarone in the *Sample solution* (mg/mL)
- \(M_{r1}\) = molecular weight of dronedarone free base, 556.76
- \(M_{r2}\) = molecular weight of dronedarone hydrochloride, 593.22

**Acceptance criteria:** 95.0%–105.0%

---

**PERFORMANCE TESTS**

**Change to read:**

- **Dissolution** (711)

**Test 1** (TBD)

**Medium:** 13.61 g/L of *monobasic potassium phosphate* in water. Adjust with 0.1 M *hydrochloric acid* or 0.1 M *sodium hydroxide* as needed to a pH of 4.5; 1000 mL

**Apparatus 2:** 75 rpm, with sinker ring

**Times:** 30 and 90 min

**Standard solution:** 0.43 mg/mL of *USP Dronedarone Hydrochloride RS* prepared as follows. Dissolve a suitable amount of *USP Dronedarone Hydrochloride RS* in 2% of the total volume of *methanol* and dilute with *Medium* to volume.

**Sample solution:** Pass a portion of sample under test through a suitable filter.

**Instrumental conditions**

- **Analytical wavelength:** UV 288 nm

- **Cell:** 1 mm

- **Blank:** *Medium*

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of dronedarone dissolved:

\[
\text{Result} = \left(\frac{A_U}{A_S}\right) \times C_S \times V \times \left(\frac{1}{L}\right) \times \left(\frac{M_{r1}}{M_{r2}}\right) \times 100
\]

- \(A_U\) = absorbance from the *Sample solution*
- \(A_S\) = absorbance from the *Standard solution*
- \(C_S\) = concentration of *USP Dronedarone Hydrochloride RS* in the *Standard solution* (mg/mL)
- \(V\) = volume of *Medium*, 1000 mL
- \(L\) = label claim (mg/Tablet)
- \(M_{r1}\) = molecular weight of dronedarone free base, 556.76
- \(M_{r2}\) = molecular weight of dronedarone hydrochloride, 593.22

**Tolerances**

- **30 min:** 20.0%–60.0% of the labeled amount of dronedarone free base \((C_{31}H_{44}N_2O_5S)\) is dissolved.
- **90 min:** NLT 80% \((Q)\) of the labeled amount of dronedarone free base \((C_{31}H_{44}N_2O_5S)\) is dissolved.
Test 4: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 4.

Medium: 6.8 g/L of potassium phosphate monobasic in water. The pH of the resulting solution should be 4.5; 1000 mL, deaerated.

Apparatus 2: 50 rpm

Times: 30 and 60 min

Buffer: 7.8 g/L of sodium phosphate monobasic dihydrate in water. Add 2 mL of triethylamine to each liter of the solution. Adjust with phosphoric acid to a pH of 2.2.

Mobile phase: Acetonitrile and Buffer (55:45)

Standard stock solution: 8.52 mg/mL of USP Dronedarone Hydrochloride RS in acetonitrile. Sonicate to dissolve.

Standard solution: 0.426 mg/mL of USP Dronedarone Hydrochloride RS from Standard stock solution in Medium

Sample solution: At the times specified, withdraw 10 mL of the solution under test and replace with 10 mL of Medium. Pass the solution under test through a suitable filter of 0.45-μm pore size, discarding the first 2 mL of filtrate.

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 230 nm

Column: 4.6-mm × 25-cm; 5-μm packing L1

Temperatures
Autosampler: 15°
Column: 40°

Flow rate: 1.5 mL/min

Injection volume: 10 μL

Run time: NLT 2 times the retention time of dronedarone

System suitability
Sample: Standard solution

Suitability requirements
Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis
Samples: Standard solution and Sample solution

Calculate the concentration \( C_i \) of dronedarone \( (C_{31}H_{44}N_2O_5S) \) in the sample withdrawn from the vessel at each time point \( i \):

\[
\text{Result}_i = \left( \frac{r_U}{r_S} \right) \times C_S \times \left( \frac{M_{r1}}{M_{r2}} \right)
\]

\( r_U \) = peak response of dronedarone from the Sample solution
\( r_S \) = peak response of dronedarone from the Standard solution
\( C_S \) = concentration of USP Dronedarone Hydrochloride RS in the Standard solution (mg/mL)

\( M_{r1} \) = molecular weight of dronedarone, 556.76
\( M_{r2} \) = molecular weight of dronedarone hydrochloride, 593.22

Calculate the percentage of the labeled amount of dronedarone \( (C_{31}H_{44}N_2O_5S) \) dissolved at each time point \( i \):

\[
\text{Result}_i = C_1 \times V \times \left( \frac{1}{L} \right) \times 100
\]
\[
\text{Result}_2 = [(C_2 \times V) + (C_1 \times V_s)] \times (1/L) \times 100
\]

\(C_i\) = concentration of dronedarone in the portion of sample withdrawn at time point \(i\) (mg/mL)

\(V\) = volume of the Medium, 1000 mL

\(L\) = label claim (mg/Tablet)

\(V_s\) = volume of the sample solution withdrawn at each time point and replaced with Medium (mL)

**Tolerances:** See Table 1.

<table>
<thead>
<tr>
<th>Time Point ((i))</th>
<th>Time (min)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>30</td>
<td>50–72</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>NLT 80 (Q)↑ (TBD)</td>
</tr>
</tbody>
</table>

**Uniformity of Dosage Units (905):** Meet the requirements

**Impurities**

- **Organic Impurities**
  - **Buffer, Mobile phase, and System suitability stock solution:** Proceed as directed in the Assay.
  - **System suitability solution:** 0.01 mg/mL each of USP Dronedarone Hydrochloride RS and USP Dronedarone Related Compound A RS prepared as follows. To a suitable amount of System suitability stock solution, add 20% of the total volume of methanol and dilute with Mobile phase to volume.
  - **Standard stock solution:** 0.4 mg/mL of USP Dronedarone Hydrochloride RS in methanol
  - **Standard solution:** 0.002 mg/mL of USP Dronedarone Hydrochloride RS prepared as follows. To a suitable amount of Standard stock solution, add 25% of the total volume of methanol and dilute with Mobile phase to volume.
  - **Sensitivity solution:** 0.0005 mg/mL of USP Dronedarone Hydrochloride RS prepared as follows. To a suitable amount of the Standard solution, add 20% of the total volume of methanol and dilute with Mobile phase to volume.
  - **Sample stock solution:** Nominally equivalent to 4 mg/mL of dronedarone in methanol prepared as follows. Dissolve and dilute in methanol to volume, an amount equivalent to 400 mg of dronedarone from NLT 20 finely powdered Tablets, taken in a 100-mL volumetric flask. Sonicate for about 5 min and allow to settle at room temperature.
  - **Sample solution:** Nominally equivalent to 1 mg/mL of dronedarone in Mobile phase from Sample stock solution. Pass through a suitable filter of 0.45-µm pore size and discard the first 3 mL of the filtrate.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

- **Mode:** LC
- **Detector:** UV 246 nm
- **Column:** 4.6-mm × 25-cm; 5-µm packing L10
- **Flow rate:** 0.8 mL/min
- **Injection volume:** 20 µL
- **Run time:** NLT 3.6 times the retention time of dronedarone

**System suitability**

- **Samples:** System suitability solution and Sensitivity solution
The relative retention times for dronedarone related compound A and dronedarone are 0.7 and 1.0, respectively.

**Suitability requirements**

**Resolution:** NLT 8 between dronedarone and dronedarone related compound A, *System suitability solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Tablets taken:

\[
\left( \frac{r_U}{r_S} \right) \times \left( \frac{C_S}{C_U} \right) \times \left( \frac{M_{r1}}{M_{r2}} \right) \times 100
\]

- \( r_U \) = peak response of each impurity from the *Sample solution*
- \( r_S \) = peak response of dronedarone from the *Standard solution*
- \( C_S \) = concentration of **USP Dronedarone Hydrochloride RS** in the *Standard solution* (mg/mL)
- \( C_U \) = nominal concentration of dronedarone in the *Sample solution* (mg/mL)
- \( M_{r1} \) = molecular weight of dronedarone free base, 556.76
- \( M_{r2} \) = molecular weight of dronedarone hydrochloride, 593.22

**Acceptance criteria:** Disregard peaks less than 0.05%.

- **Any unspecified impurity:** NMT 0.20%
- **Total impurities:** NMT 0.4%

**ADDITIONAL REQUIREMENTS**

- **Packaging and Storage:** Store at controlled room temperature.

**Add the following:**

- **Labeling:** When more than one *Dissolution* test is given, the labeling states the test used only if *Test 1* is not used.  *(TBD)*

- **USP Reference Standards** *(11)*
  - **USP Dronedarone Hydrochloride RS**
  - **USP Dronedarone Related Compound A RS**
  - **N-(2-Butyl-3-{4-[3-(butylamino)propoxy]benzoyl}benzofuran-5-yl) methanesulfonamide.**
  - \( C_{27}H_{36}N_2O_5S \) 500.65

---

[Page Information: Not Applicable]

[Current DocID: © The United States Pharmacopeial Convention All Rights Reserved.]